Brief: BioXcel Therapeutics Q2 Basic EPS USD -0.21 Vs. IBES Estimate USD -0.71
06/08/2024 12:00
Aug 06 (Reuters) - BioXcel Therapeutics Q2 revenue USD 1.104 million vs. IBES estimate USD 759.2 thousand. * Q2 operating income USD -17.296 million vs. IBES estimate USD -22.7 million * Q2 net income USD -8.299 million vs. IBES estimate USD -25.8 million * Q2 operating expenses USD 18.4 million
Recent news on BioXcel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
Brief: Bioxcel Therapeutics Enters Into Asset Sale Agreement With Teva Pharmaceuticals
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna, Ulta Beauty